Fraser, G <br/><br/>
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.  [electronic resource] 

 -  Leukemia  04 2019 
 - 969-980 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5551 
<br/><br/><label>Standard No.: </label>10.1038/s41375-018-0276-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--analogs & derivatives<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bendamustine Hydrochloride--administration & dosage<br/>Double-Blind Method<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Leukemia, Lymphocytic, Chronic, B-Cell--drug therapy<br/>Male<br/>Middle Aged<br/>Piperidines<br/>Prognosis<br/>Pyrazoles--administration & dosage<br/>Pyrimidines--administration & dosage<br/>Rituximab--administration & dosage<br/>Survival Rate<br/>Young Adult